Antiangiogenic therapy through copper chelation.
As new compounds are being evaluated for use in clinical trials involving antiangiogenic therapies, two important factors must be considered. Independent of clinical efficacy, the potential drug must be cost-effective and have reasonable ease of production. The compound endostatin (Entremed, Inc.) has recently completed two Phase I trials with minimal toxicity to the patients treated [1,2]. However, due to the difficulty and expense of producing large quantities of a recombinant protein, Entremed Inc. has experienced financial difficulties [3]. As this company's fate indicates, a drug must not only be clinically effective, but must also possess reasonable production economics. Another interesting component of compound development is selectivity. Highly selective antiangiogenic compounds such as the tyrosine kinase inhibitor SU-5416 are being replaced by less selective compounds such as SU-6668, which acts on a broader spectrum of tyrosine kinase receptors [4]. This move towards using less selective antiangiogenic compounds is based on preclinical models that demonstrate both better clinical efficacy when using less specific molecules and low response rates from the more selective compounds. With the aim of further examining broadly-acting antiangiogenic agents, the authors are currently evaluating new classes of agents that preferentially bind copper and inhibit angiogenesis. Copper has been known to be a significant target for antiangiogenic therapy for a number of years [5]. Recently, through the use of molecular techniques, the target enzymes that utilise copper as a cofactor are being elucidated. This review will describe the historical use of anticopper therapy for the treatment of Wilson's disease and evaluate some of the new anticopper compounds currently under consideration for use in antiangiogenic therapy.
Sproull
Mary
M
Imaging and Molecular Therapeutics Section, Radiation Oncology Branch, Radiation Oncology Sciences Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, B3B69, Bethesda, MD, USA.
Brechbiel
Martin
M
Camphausen
Kevin
K
D020533:Angiogenesis Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D002614:Chelating Agents / Q000494:pharmacology / Q000627:therapeutic use*; D015913:Chelation Therapy; D003300:Copper; D016510:Corneal Neovascularization / Q000188:drug therapy; D003514:Cyclohexylamines / Q000494:pharmacology / Q000627:therapeutic use; D006527:Hepatolenticular Degeneration / Q000188:drug therapy; D006801:Humans; D008982:Molybdenum / Q000494:pharmacology / Q000627:therapeutic use; D009369:Neoplasms / Q000098:blood supply / Q000188:drug therapy; D009389:Neovascularization, Pathologic / Q000188:drug therapy; D010396:Penicillamine / Q000494:pharmacology / Q000627:therapeutic use; D011725:Pyridines / Q000494:pharmacology / Q000627:therapeutic use; D011817:Rabbits; D014266:Trientine / Q000494:pharmacology / Q000627:therapeutic use
D020533:Angiogenesis Inhibitors; D002614:Chelating Agents; D003514:Cyclohexylamines; D011725:Pyridines; C114047:tachpyr; D003300:Copper; D008982:Molybdenum; C020809:tetrathiomolybdate; D010396:Penicillamine; D014266:Trientine